While Arena Pharmaceuticals (ARNA +0.00%) and VIVUS (VVUS +0.00%), makers of the obesity drugs Belviq and Qsymia, respectively, both garner a lot of attention on Fool.com, they also have attracted the attention of the short sellers. In this video, Motley Fool health-care analyst David Williamson talks about the "buy the run-up, short the launch" trend, and whether the short-sellers are right not to believe in these stocks.
Are the Shorts Right About Obesity Drugs?
By Dave Williamson and Max Macaluso – Dec 18, 2012 at 6:30PM
NASDAQ: ARNA
Arena Pharmaceuticals
The two obesity-drug makers have caught the attention of short sellers. Are they right?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid